The two sides expect the deal to close by the end of 2022.
In June, the Food and Drug Administration rejected Spero’s Tebipenem application.
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
Pfizer’s Viagra generic to sell for half the price; GSK seeks oncology deals; Ionis’ experimental Huntington’s drug tackles toxic protein for the first time
A panel recommends the U.S. government license a hepatitis-C therapy; the FDA approves Roche MS drug; new eczema drug to cost $37,000 per year
Get the most out of
Register for free and enjoy unlimited access to: